Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diabetes

  Free Subscription


Articles published in Ophthalmology

Retrieve available abstracts of 25 articles:
HTML format
Text format



Single Articles


    October 2018
  1. MALONEY MH, Schilz SR, Herrin J, Sangaralingham LR, et al
    Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice.
    Ophthalmology. 2018 Oct 4. pii: S0161-6420(18)30063.
    PubMed     Text format     Abstract available


    September 2018
  2. SRIVASTAV K, Baskaran P
    Re: Zur et al.: OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant (Ophthalmology. 2018;125:267-275).
    Ophthalmology. 2018;125:e61.
    PubMed     Text format    


    August 2018
  3. NAKASHIMA H, Iwama Y, Tanioka K, Emi K, et al
    Paracentral Acute Middle Maculopathy following Vitrectomy for Proliferative Diabetic Retinopathy: Incidence, Risk Factors, and Clinical Characteristics.
    Ophthalmology. 2018 Aug 17. pii: S0161-6420(18)30905.
    PubMed     Text format     Abstract available


  4. SUN JK, Glassman AR, Beaulieu WT, Stockdale CR, et al
    Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
    Ophthalmology. 2018 Aug 7. pii: S0161-6420(18)31489.
    PubMed     Text format     Abstract available


  5. OBEID A, Su D, Patel SN, Uhr JH, et al
    Outcomes of Eyes Lost to Follow-Up with Proliferative Diabetic Retinopathy that received Panretinal Photocoagulation vs Intravitreal Anti-Vascular Endothelial Growth Factor.
    Ophthalmology. 2018 Aug 2. pii: S0161-6420(18)31079.
    PubMed     Text format     Abstract available


    July 2018
  6. BRESSLER SB, Beaulieu WT, Glassman AR, Gross JG, et al
    Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Ophthalmology. 2018 Jul 3. pii: S0161-6420(18)30577.
    PubMed     Text format     Abstract available


    May 2018
  7. KLEIN R, Lee KE, Danforth L, Tsai MY, et al
    The Relationship of Retinal Vessel Geometric Characteristics to the Incidence and Progression of Diabetic Retinopathy.
    Ophthalmology. 2018 May 17. pii: S0161-6420(18)30530.
    PubMed     Text format     Abstract available


  8. WONG TY, Sun J, Kawasaki R, Ruamviboonsuk P, et al
    Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings.
    Ophthalmology. 2018 May 15. pii: S0161-6420(17)33523.
    PubMed     Text format     Abstract available


  9. REDDY RK, Pieramici DJ, Gune S, Ghanekar A, et al
    Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Ophthalmology. 2018 May 8. pii: S0161-6420(17)33607.
    PubMed     Text format     Abstract available


  10. PAYNE JF, Clark WL, Bruce BB, Wykoff CC, et al
    Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.
    Ophthalmology. 2018 May 2. pii: S0161-6420(18)30678.
    PubMed     Text format    


    March 2018
  11. LIN J, Chang JS, Yannuzzi NA, Smiddy WE, et al
    Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
    Ophthalmology. 2018 Mar 29. pii: S0161-6420(18)30040.
    PubMed     Text format     Abstract available


  12. OBEID A, Gao X, Ali FS, Talcott KE, et al
    Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.
    Ophthalmology. 2018 Mar 29. pii: S0161-6420(17)33569.
    PubMed     Text format     Abstract available


  13. YANNUZZI NA, Sridhar J, Chang JS, Lin J, et al
    Cost Evaluation of Laser versus Intravitreal Aflibercept for Proliferative Diabetic Retinopathy.
    Ophthalmology. 2018 Mar 20. pii: S0161-6420(18)30299.
    PubMed     Text format    


  14. GUPTA P, Liang Gan AT, Kidd Man RE, Fenwick EK, et al
    Impact of Incidence and Progression of Diabetic Retinopathy on Vision-Specific Functioning.
    Ophthalmology. 2018 Mar 20. pii: S0161-6420(17)32967.
    PubMed     Text format     Abstract available


  15. JAMPOL LM, Glassman AR, Liu D, Aiello LP, et al
    Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Ophthalmology. 2018 Mar 7. pii: S0161-6420(17)32232.
    PubMed     Text format     Abstract available


  16. KRAUSE J, Gulshan V, Rahimy E, Karth P, et al
    Grader Variability and the Importance of Reference Standards for Evaluating Machine Learning Models for Diabetic Retinopathy.
    Ophthalmology. 2018 Mar 2. pii: S0161-6420(17)32698.
    PubMed     Text format     Abstract available


    February 2018
  17. LIU L, Tham YC
    Re: Keel et al.: The prevalence of diabetic retinopathy in Australian adults with self-reported diabetes: The National Eye Health Survey (Ophthalmology. 2017;124:977-984).
    Ophthalmology. 2018;125:e13-e14.
    PubMed     Text format    


    January 2018
  18. FIGUEIRA J, Fletcher E, Massin P, Silva R, et al
    Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Ophthalmology. 2018 Jan 27. pii: S0161-6420(17)32188.
    PubMed     Text format     Abstract available


  19. BROWN DM, Ou WC, Wong TP, Kim RY, et al
    Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Ophthalmology. 2018 Jan 11. pii: S0161-6420(17)31641.
    PubMed     Text format     Abstract available


  20. GRZYBOWSKI A, Kanclerz P
    Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: result of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
    Ophthalmology. 2018;125:e8-e9.
    PubMed     Text format    


  21. JONNA G, Kim SJ
    Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
    Ophthalmology. 2018;125:e4.
    PubMed     Text format    


  22. MODJTAHEDI BS, Fong DS
    Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
    Ophthalmology. 2018;125:e10-e11.
    PubMed     Text format    


    December 2017
  23. TAN GS, Gan A, Sabanayagam C, Tham YC, et al
    Ethnic Differences in the Prevalence and Risk Factors of Diabetic Retinopathy: The Singapore Epidemiology of Eye Diseases Study.
    Ophthalmology. 2017 Dec 4. pii: S0161-6420(17)31893.
    PubMed     Text format     Abstract available


  24. THOMAS M, Rao RC, Johnson MW, Paulus YM, et al
    Re: Bressler et al.: Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab (Ophthalmology. 2017;124:431-439).
    Ophthalmology. 2017;124:e87-e88.
    PubMed     Text format    


    September 2017
  25. ZUR D, Iglicki M, Busch C, Invernizzi A, et al
    Optical Coherence Tomography Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant.
    Ophthalmology. 2017 Sep 18. pii: S0161-6420(17)32014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: